000			02119nam a22004577a 4500
008			240807s20242024 xxu||||| |||| 00| 0 eng d
022			_a2041-1723
024			_a10.1038/s41467-024-48359-1 [pii]
024			_aPMC11087457 [pmc]
040			_aOvid MEDLINE(R)
099			_a38730268
245			_aAuthor Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
251			_aNature communications . 15(1):3957, 2024 May 10.
252			_aNat Commun. 15(1):3957, 2024 May 10.
253			_aNature communications
260			_c2024
260			_fFY2024
260			_p2024 May 10
265			_sepublish
265			_tPubMed-not-MEDLINE
266			_d2024-08-07
266			_z2024/05/10 23:35
546			_aEnglish
650			_zAutomated
651			_aMedStar Washington Hospital Center
656			_aAssociate Dean for Research Development
656			_aHematology/Oncology
656			_aMedStar Health
657			_aPublished Erratum
700			_aChitalia, Ami _bMWHC
700			_aGallagher, Christopher _bMWHC
700			_aSchlam, Ilana _bMWHC
700			_aSwain, Sandra M _bMSH
790			_aLynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C
856			_uhttps://dx.doi.org/10.1038/s41467-024-48359-1 _zhttps://dx.doi.org/10.1038/s41467-024-48359-1
858			_yChitalia, Ami _uhttp://orcid.org/0009-0001-0274-2150 _zhttp://orcid.org/0009-0001-0274-2150
858			_yGallagher, Christopher _uhttp://orcid.org/0000-0002-3846-5052 _zhttp://orcid.org/0000-0002-3846-5052
858			_ySchlam, Ilana _uhttp://orcid.org/0000-0003-4996-0400 _zhttp://orcid.org/0000-0003-4996-0400
858			_ySwain, Sandra M _uhttp://orcid.org/0000-0002-1320-3830 _zhttp://orcid.org/0000-0002-1320-3830
942			_cART _dArticle
999			_c14509 _d14509